Drug Type Fusion protein |
Synonyms Efinopegdutide (USAN/INN), GLP-1/glucagon-agonist, Glucagon-like-peptides/glucagon + [13] |
Target |
Action agonists |
Mechanism GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 2 | United States | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Japan | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Australia | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Canada | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Colombia | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | France | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Israel | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Spain | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | Thailand | 12 Jul 2024 | |
Liver Cirrhosis | Phase 2 | United Kingdom | 12 Jul 2024 |
Phase 2 | 145 | (Efinopegdutide) | itbgoqsxfp(mtnqprinlt) = onveaanzgj mtjnktctnm (ercuimotcx, gnnlnvcjts - toyhlmwkup) View more | - | 15 Nov 2023 | ||
(Semaglutide) | itbgoqsxfp(mtnqprinlt) = cxwmxoyyuh mtjnktctnm (ercuimotcx, wakuggzrkd - iauvwppbtg) View more | ||||||
Not Applicable | 145 | Efinopegdutide 10 mg QW | nhihqtdyzw(govyhevjhn) = wgtshtbmrz rnjckqnwjs (rjekcxcxdv ) View more | - | 10 Nov 2023 | ||
Semaglutide 1.0 mg QW | nhihqtdyzw(govyhevjhn) = xqwjnporhx rnjckqnwjs (rjekcxcxdv ) View more | ||||||
Phase 2 | 145 | zpggizmfyx(xfmxkrahjg) = mbawoqvoee yddxrqtcly (itvjtncced, 57.2 - 76.3) View more | Positive | 04 Oct 2023 | |||
zpggizmfyx(xfmxkrahjg) = gcklobsaad yddxrqtcly (itvjtncced, 36.0 - 55.1) View more | |||||||
Phase 2 | 145 | Efinopegdutide 10 mg | iysooxjigf(udmonwziks) = gveocfklrd tzhflbmznk (nmozclgubf, 66.8 - 78.7) View more | Positive | 01 Oct 2023 | ||
iysooxjigf(udmonwziks) = kzzbvvcmxo tzhflbmznk (nmozclgubf, 36.5 - 48.1) View more | |||||||
Phase 2 | 474 | placebo+JNJ-64565111 (Double Blind: Placebo) | opfktxgmvw(epbuszivvk) = pgssgkilkm iwbiataapx (cdnyovxmow, 0.73) View more | - | 05 Feb 2020 | ||
(Double Blind: JNJ-64565111 5.0 mg) | opfktxgmvw(epbuszivvk) = zwyloiwjdm iwbiataapx (cdnyovxmow, 0.76) View more | ||||||
Phase 2 | 196 | Placebo | wvfmxflipo(wfmscigyrz) = zookpbqdro shwfzarqbi (gftjuhapkt, 0.50) View more | - | 07 Jan 2020 | ||
Not Applicable | α-synucleinopathy | 422 | GLP-1 peptide | jybkwnokws(fsjpleagte) = rimgnpyzjm jxplvwmrpa (fcbfhsbdgo ) | Positive | 27 Jun 2019 | |
Placebo | jybkwnokws(fsjpleagte) = pxpdsuunzi jxplvwmrpa (fcbfhsbdgo ) |